Robert Gut Sells 2,726 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) Director Robert Gut sold 2,726 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total transaction of $73,765.56. Following the transaction, the director owned 32,259 shares in the company, valued at approximately $872,928.54. This trade represents a 7.79% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Robert Gut also recently made the following trade(s):

• On Wednesday, June 10th, Robert Gut sold 7,552 shares of uniQure stock. The stock was sold at an average price of $26.05, for a total transaction of $196,729.60.

uniQure Stock Performance

Shares of QURE opened at $27.57 on Friday. The company’s fifty day moving average is $22.52 and its 200-day moving average is $21.80. uniQure N.V. has a 12 month low of $8.73 and a 12 month high of $71.50. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The company had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. Equities analysts expect that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Key uniQure News

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Institutional Trading of uniQure

Large investors have recently modified their holdings of the company. Torren Management LLC bought a new stake in shares of uniQure during the 4th quarter worth $28,000. Jones Financial Companies Lllp boosted its holdings in uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares during the period. IFP Advisors Inc bought a new stake in uniQure in the 4th quarter valued at $48,000. Smartleaf Asset Management LLC bought a new stake in uniQure in the 4th quarter valued at $48,000. Finally, CIBC Private Wealth Group LLC bought a new stake in uniQure in the 3rd quarter valued at $50,000. 78.83% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. TD Cowen restated a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Wolfe Research assumed coverage on shares of uniQure in a report on Monday, February 23rd. They set a “peer perform” rating for the company. Stifel Nicolaus set a $28.00 price objective on shares of uniQure in a report on Tuesday, May 5th. Royal Bank Of Canada raised shares of uniQure from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $11.00 to $35.00 in a report on Monday, March 9th. Finally, Chardan Capital upped their price objective on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, uniQure has a consensus rating of “Moderate Buy” and an average target price of $42.83.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.